Drugmakers Comment on FDA’s Guidance on Natural Histories for Rare Diseases 

Drug Industry Daily
A A
Ionis, Merck and Lundbeck offered feedback on the FDA’s guidance for developing natural history studies for rare disease drug development, praising some parts of the guidance but calling for more details.

To View This Article:

Login

Subscribe To Drug Industry Daily